nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

20.06.2020 | COVID-19 | Editorial Zur Zeit gratis

A metastatic tumor is no different to a viral pandemic: lessons learnt from COVID-19 may teach us to change the PRRT paradigm

verfasst von: Giovanni Paganelli, Lisa Bodei, Irvin Modlin

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 10/2020

Einloggen, um Zugang zu erhalten

Auszug

Peptide Receptor RadioTherapy (PRRT) came of age with the first official announcement in 2015 when the results of the NETTER-1 randomized trial [1, 2] became available. This demonstrated that second-line therapy with [¹⁷⁷Lu]Lu-DOTA-TATE was significantly more efficient than high-dose somatostatin analogs (SSAs) in decreasing the risk of progression of metastatic small-bowel neuroendocrine tumors (NETs), receiving standard SSA dosage. Those of us who had already been using PRRT effectively for 20 years were underwhelmed by this pronouncement. It was like listening to the result of a football game being announced a week after we had watched the match. …

Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Chaplin M, et al. O-009 NETTER-1 phase III: efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate. Ann Oncol. 2016;27:ii121. https://doi.org/10.1093/annonc/mdw198.09.CrossRef

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35. https://doi.org/10.1056/NEJMoa1607427.CrossRefPubMedPubMedCentral

Krenning EPKP, Bakker WH, Breeman WA, Postema PT, Kwekkeboom DJ, Oei HY, et al. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history. Ann N Y Acad Sci. 1994;15:496–506.CrossRef

Paganelli GZS, Cremonesi M, Bodei L, Ferrari M, Grana C, Bartolomei M, et al. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med. 2001;28:426–34.CrossRef

Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2003;30:417–22. https://doi.org/10.1007/s00259-002-1050-8.CrossRefPubMedPubMedCentral

Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with (1)(7)(7)Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38:2125–35. https://doi.org/10.1007/s00259-011-1902-1.CrossRefPubMed

Bodei L, Kidd MS, Singh A, van der Zwan WA, Severi S, Drozdov IA, et al. PRRT genomic signature in blood for prediction of (177)Lu-octreotate efficacy. Eur J Nucl Med Mol Imaging. 2018;45:1155–69. https://doi.org/10.1007/s00259-018-3967-6.CrossRefPubMedPubMedCentral

Bodei L, Kidd MS, Singh A, van der Zwan WA, Severi S, Drozdov IA, et al. PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest. Eur J Nucl Med Mol Imaging. 2020;47:895–906. https://doi.org/10.1007/s00259-019-04601-3.CrossRefPubMed

Bahri H, Laurence L, Edeline J, Leghzali H, Devillers A, Raoul JL, et al. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation. J Nucl Med. 2014;55:1786–90. https://doi.org/10.2967/jnumed.114.144386.CrossRefPubMed

10.

Severi SNO, Bodei L, Sansovini M, Ianniello A, Nicoletti S, Scarpi E, et al. Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:881–8.CrossRef

11.

Pavel M, O’Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103:172–85. https://doi.org/10.1159/000443167.CrossRefPubMed

12.

NCCN. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Neuroendocrine and adrenal tumors, Version 1.2019 - March 5, 2019. p. https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf.

13.

Capdevila J, Hernando J, Perez-Hoyos S, Roman-Gonzalez A, Grande E. Meta-analysis of randomized clinical trials comparing active treatment with placebo in metastatic neuroendocrine tumors. Oncologist. 2019;24:e1315–e20. https://doi.org/10.1634/theoncologist.2018-0675.CrossRefPubMedPubMedCentral

14.

Paganelli G, Sansovini M, Nicolini S, Grassi I, Ibrahim T, Amadori E, et al. 177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study. Eur J Nucl Med. 2020. https://doi.org/10.1007/s00259-020-04873-0

15.

Hudis C, Dang C. The development of dose-dense adjuvant chemotherapy. Breast J. 2015;21:42–51. https://doi.org/10.1111/tbj.12364.CrossRefPubMed

16.

Hill RP. The changing paradigm of tumour response to irradiation. Br J Radiol. 2017;90:20160474. https://doi.org/10.1259/bjr.20160474.CrossRefPubMed

17.

Sansovini M, Severi S, Ianniello A, Nicolini S, Fantini L, Mezzenga E, et al. Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with (177)Lu-D OTATATE. Eur J Nucl Med Mol Imaging. 2017;44:490–9. https://doi.org/10.1007/s00259-016-3533-z.CrossRefPubMed

18.

Bodei L, Kidd M, Baum RP, Modlin IM. PRRT: defining the paradigm shift to achieve standardization and individualization. J Nucl Med. 2014;55:1753–6. https://doi.org/10.2967/jnumed.114.143974.CrossRefPubMed

Titel: A metastatic tumor is no different to a viral pandemic: lessons learnt from COVID-19 may teach us to change the PRRT paradigm
verfasst von: Giovanni Paganelli
Lisa Bodei
Irvin Modlin
Publikationsdatum: 20.06.2020
Verlag: Springer Berlin Heidelberg
Schlagwort: COVID-19
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 10/2020
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-020-04904-w

Prediction of lithium treatment response in bipolar depression using 5-HTT and 5-HT1A PET

Original Article

PET imaging of beta-secretase 1 in the human brain: radiation dosimetry, quantification, and test-retest examination of [18F]PF-06684511

Open Access
Original Article

Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice

Open Access
Original Article

Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy

Open Access
Original Article

The added benefit of contrast-enhanced CT in evaluation of incidental FDG-avid colon lesions

Letter to the Editor

Lymphangioleiomyomatosis revealed by 68Ga-NOTA-Evans Blue PET/CT

Image of the Month

Springer Medizin

A metastatic tumor is no different to a viral pandemic: lessons learnt from COVID-19 may teach us to change the PRRT paradigm

Auszug

Weitere Artikel der Ausgabe 10/2020

Prediction of lithium treatment response in bipolar depression using 5-HTT and 5-HT1A PET

PET imaging of beta-secretase 1 in the human brain: radiation dosimetry, quantification, and test-retest examination of [18F]PF-06684511

Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice

Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy

The added benefit of contrast-enhanced CT in evaluation of incidental FDG-avid colon lesions

Lymphangioleiomyomatosis revealed by 68Ga-NOTA-Evans Blue PET/CT

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Prediction of lithium treatment response in bipolar depression using 5-HTT and 5-HT1A PET

PET imaging of beta-secretase 1 in the human brain: radiation dosimetry, quantification, and test-retest examination of [18F]PF-06684511

Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice

Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy

The added benefit of contrast-enhanced CT in evaluation of incidental FDG-avid colon lesions

Lymphangioleiomyomatosis revealed by 68Ga-NOTA-Evans Blue PET/CT